Published in Prog Neuropsychopharmacol Biol Psychiatry on August 01, 2003
A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest (2005) 3.44
CNS immune privilege: hiding in plain sight. Immunol Rev (2006) 3.13
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener (2009) 2.23
Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study. Neurology (2007) 2.05
Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimer's disease. J Neuroinflammation (2011) 1.68
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. J Neuroinflammation (2008) 1.59
In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain (2013) 1.57
Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostaglandins Leukot Essent Fatty Acids (2007) 1.50
Fibrillar amyloid-beta peptides activate microglia via TLR2: implications for Alzheimer's disease. J Immunol (2008) 1.47
White matter is altered with parental family history of Alzheimer's disease. Alzheimers Dement (2010) 1.45
Decreased expression of CD200 and CD200 receptor in Alzheimer's disease: a potential mechanism leading to chronic inflammation. Exp Neurol (2008) 1.44
Flavonoids and brain health: multiple effects underpinned by common mechanisms. Genes Nutr (2009) 1.40
Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration. Antioxid Redox Signal (2009) 1.34
Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci (2008) 1.29
Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease. Biochim Biophys Acta (2010) 1.24
A review of experimental evidence linking neurotoxic organophosphorus compounds and inflammation. Neurotoxicology (2012) 1.22
Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 1.22
Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. J Neuroinflammation (2006) 1.20
Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics. J Neurochem (2007) 1.18
The interleukin-1 signalling pathway in astrocytes: a key contributor to inflammation in the brain. J Anat (2005) 1.15
Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol (2009) 1.14
Altered arachidonic acid cascade enzymes in postmortem brain from bipolar disorder patients. Mol Psychiatry (2009) 1.14
Fibrillar beta-amyloid peptide Abeta1-40 activates microglial proliferation via stimulating TNF-alpha release and H2O2 derived from NADPH oxidase: a cell culture study. J Neuroinflammation (2006) 1.06
Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem (2010) 1.05
Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease. J Neurosci (2015) 1.03
Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain. Am J Pathol (2011) 1.02
The neuroprotective effects of cocoa flavanol and its influence on cognitive performance. Br J Clin Pharmacol (2013) 1.02
Stem cells for skeletal muscle repair. Philos Trans R Soc Lond B Biol Sci (2011) 1.01
Neutralization of granulocyte macrophage colony-stimulating factor decreases amyloid beta 1-42 and suppresses microglial activity in a transgenic mouse model of Alzheimer's disease. Hum Mol Genet (2009) 1.01
Inflammatory markers and neuropsychological functioning: the Framingham Heart Study. Neuroepidemiology (2011) 0.99
Lovastatin inhibits amyloid precursor protein (APP) beta-cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. J Neurochem (2008) 0.99
Obovatol attenuates microglia-mediated neuroinflammation by modulating redox regulation. Br J Pharmacol (2010) 0.99
Cyclooxygenases-1 and -2 differentially modulate leukocyte recruitment into the inflamed brain. Pharmacogenomics J (2009) 0.98
Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement (2013) 0.98
Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century. Curr Neuropharmacol (2013) 0.97
Inhibitory effect of 4-O-methylhonokiol on lipopolysaccharide-induced neuroinflammation, amyloidogenesis and memory impairment via inhibition of nuclear factor-kappaB in vitro and in vivo models. J Neuroinflammation (2012) 0.96
Galactic cosmic radiation leads to cognitive impairment and increased aβ plaque accumulation in a mouse model of Alzheimer's disease. PLoS One (2012) 0.96
Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis (2011) 0.94
(11)C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiol Aging (2016) 0.94
Intra-hippocampal transplantation of neural precursor cells with transgenic over-expression of IL-1 receptor antagonist rescues memory and neurogenesis impairments in an Alzheimer's disease model. Neuropsychopharmacology (2013) 0.93
Flavonoid-based therapies in the early management of neurodegenerative diseases. Adv Nutr (2015) 0.93
A refined in vitro model to study inflammatory responses in organotypic membrane culture of postnatal rat hippocampal slices. J Neuroinflammation (2005) 0.93
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Abeta peptide-induced inflammatory mediators in astroglia. J Neuroinflammation (2005) 0.93
Cognitive dysfunction with aging and the role of inflammation. Ther Adv Chronic Dis (2011) 0.92
The role of inflammatory processes in Alzheimer's disease. Inflammopharmacology (2012) 0.92
A non-transgenic mouse model (icv-STZ mouse) of Alzheimer's disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol (2012) 0.91
Dexamethasone diminishes the pro-inflammatory and cytotoxic effects of amyloid beta-protein in cerebrovascular smooth muscle cells. J Neuroinflammation (2006) 0.89
Increased 3-hydroxykynurenine serum concentrations differentiate Alzheimer's disease patients from controls. Eur Arch Psychiatry Clin Neurosci (2012) 0.89
Developing new treatments for Alzheimer's disease: the who, what, when, and how of biomarker-guided therapies. Int Psychogeriatr (2008) 0.89
Intracellular- and extracellular-derived Ca(2+) influence phospholipase A(2)-mediated fatty acid release from brain phospholipids. Biochim Biophys Acta (2009) 0.89
The mTOR Inhibitor Rapamycin Mitigates Perforant Pathway Neurodegeneration and Synapse Loss in a Mouse Model of Early-Stage Alzheimer-Type Tauopathy. PLoS One (2015) 0.89
Cognitive deficit associated with cholinergic and nerve growth factor down-regulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci U S A (2005) 0.88
Targeting NADPH oxidase and phospholipases A2 in Alzheimer's disease. Mol Neurobiol (2010) 0.88
'Neuroinflammation' differs categorically from inflammation: transcriptomes of Alzheimer's disease, Parkinson's disease, schizophrenia and inflammatory diseases compared. Neurogenetics (2014) 0.88
Cellular and molecular mechanisms of immunomodulation in the brain through environmental enrichment. Front Cell Neurosci (2014) 0.87
Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease. J Neuroinflammation (2012) 0.86
Pathways towards an effective immunotherapy for Parkinson's disease. Expert Rev Neurother (2011) 0.84
Mechanisms of granulin deficiency: lessons from cellular and animal models. Mol Neurobiol (2012) 0.84
Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease. J Alzheimers Dis (2016) 0.84
Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2007) 0.84
Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker? J Cell Mol Med (2008) 0.82
Smart Soup, a traditional Chinese medicine formula, ameliorates amyloid pathology and related cognitive deficits. PLoS One (2014) 0.82
Can peripheral leukocytes be used as Alzheimer's disease biomarkers? Expert Rev Neurother (2009) 0.82
Granulocyte-macrophage colony-stimulating factor antibody suppresses microglial activity: implications for anti-inflammatory effects in Alzheimer's disease and multiple sclerosis. J Neurochem (2009) 0.82
Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study. Am J Geriatr Psychiatry (2008) 0.82
Osmotin attenuates LPS-induced neuroinflammation and memory impairments via the TLR4/NFκB signaling pathway. Sci Rep (2016) 0.82
The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells. Cell Mol Neurobiol (2011) 0.81
Sulfatides facilitate apolipoprotein E-mediated amyloid-beta peptide clearance through an endocytotic pathway. J Neurochem (2008) 0.81
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J Inflamm Res (2008) 0.81
Expression and localization of prostaglandin transporter in Alzheimer disease brains and age-matched controls. J Neuroimmunol (2008) 0.81
Targeting the endocannabinoid system in Alzheimer's disease. J Alzheimers Dis (2008) 0.81
Effects of immunomodulatory substances on phagocytosis of abeta(1-42) by human microglia. Int J Alzheimers Dis (2010) 0.81
Anti-inflammatory and anti-amyloidogenic effects of a small molecule, 2,4-bis(p-hydroxyphenyl)-2-butenal in Tg2576 Alzheimer's disease mice model. J Neuroinflammation (2013) 0.81
Lipid-mediated cell signaling protects against injury and neurodegeneration. J Nutr (2010) 0.80
The pathogenic implication of abnormal interaction between apolipoprotein E isoforms, amyloid-beta peptides, and sulfatides in Alzheimer's disease. Mol Neurobiol (2010) 0.80
Time-dependent effects of hypothermia on microglial activation and migration. J Neuroinflammation (2012) 0.80
Hydrogen sulfide-induced processing of the amyloid precursor protein in SH-SY5Y human neuroblastoma cells involves the PI3-K/Akt signaling pathway. Cell Mol Neurobiol (2014) 0.80
Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study. Neuropsychiatr Dis Treat (2011) 0.79
Using animal models to determine the significance of complement activation in Alzheimer's disease. J Neuroinflammation (2004) 0.79
A survey of peptides with effective therapeutic potential in Alzheimer's disease rodent models or in human clinical studies. Mini Rev Med Chem (2012) 0.79
Chronic brain inflammation causes a reduction in GluN2A and GluN2B subunits of NMDA receptors and an increase in the phosphorylation of mitogen-activated protein kinases in the hippocampus. Mol Brain (2014) 0.79
Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease. Acta Pharmacol Sin (2011) 0.79
Chemical genetics of neuroinflammation: natural and synthetic compounds as microglial inhibitors. Inflammopharmacology (2011) 0.79
Signaling pathways mediating a selective induction of nitric oxide synthase II by tumor necrosis factor alpha in nerve growth factor-responsive cells. J Neuroinflammation (2005) 0.78
Nutrients, Microglia Aging, and Brain Aging. Oxid Med Cell Longev (2016) 0.78
Malaysian endophytic fungal extracts-induced anti-inflammation in Lipopolysaccharide-activated BV-2 microglia is associated with attenuation of NO production and, IL-6 and TNF-α expression. BMC Complement Altern Med (2015) 0.77
Lessons from Microglia Aging for the Link between Inflammatory Bone Disorders and Alzheimer's Disease. J Immunol Res (2015) 0.76
Platelets in psychiatric disorders. World J Psychiatry (2012) 0.76
Correlated inflammatory responses and neurodegeneration in peptide-injected animal models of Alzheimer's disease. Biomed Res Int (2014) 0.76
Inhibition of sPLA₂-IIA prevents LPS-induced neuroinflammation by suppressing ERK1/2-cPLA₂α pathway in mice cerebral cortex. PLoS One (2013) 0.76
Differential Effects of C1qa Ablation on Glaucomatous Damage in Two Sexes in DBA/2NNia Mice. PLoS One (2015) 0.75
Neuroprotective effects of bee venom phospholipase A2 in the 3xTg AD mouse model of Alzheimer's disease. J Neuroinflammation (2016) 0.75
Brain innate immunity in the regulation of neuroinflammation: therapeutic strategies by modulating CD200-CD200R interaction involve the cannabinoid system. Curr Pharm Des (2014) 0.75
Anti-neuroinflammatory Activity of Elephantopus scaber L. via Activation of Nrf2/HO-1 Signaling and Inhibition of p38 MAPK Pathway in LPS-Induced Microglia BV-2 Cells. Front Pharmacol (2017) 0.75
Piracetam Attenuates LPS-Induced Neuroinflammation and Cognitive Impairment in Rats. Cell Mol Neurobiol (2017) 0.75
Tumor necrosis factor α Inhibition for Alzheimer's Disease. J Cent Nerv Syst Dis (2017) 0.75
The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology (2008) 3.64
Inflammation, the complement system and the diseases of aging. Neurobiol Aging (2005) 1.70
Neuroinflammation in Alzheimer's disease and mild cognitive impairment: a field in its infancy. J Alzheimers Dis (2010) 1.68
PrP conformational transitions alter species preference of a PrP-specific antibody. J Biol Chem (2010) 1.62
Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol (2008) 1.56
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol (2006) 1.46
Abeta and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.41
Severe vascular disturbance in a case of familial brain calcinosis. Acta Neuropathol (2005) 1.38
Therapeutic approaches to inflammation in neurodegenerative disease. Curr Opin Neurol (2007) 1.38
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases. Virology (2004) 1.29
Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia (2007) 1.26
Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. J Alzheimers Dis (2008) 1.24
Alpha-synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol Aging (2006) 1.24
Amyloid-beta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem (2011) 1.22
Axonal damage and demyelination in the white matter after chronic cerebral hypoperfusion in the rat. Brain Res (2002) 1.21
Effects of hydrogen sulfide-releasing L-DOPA derivatives on glial activation: potential for treating Parkinson disease. J Biol Chem (2010) 1.20
Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20
Astrocytes are GABAergic cells that modulate microglial activity. Glia (2011) 1.19
Depletion of GSH in glial cells induces neurotoxicity: relevance to aging and degenerative neurological diseases. FASEB J (2010) 1.18
Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp Neurol (2004) 1.18
Persisting atypical and cystic forms of Borrelia burgdorferi and local inflammation in Lyme neuroborreliosis. J Neuroinflammation (2008) 1.18
Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J (2006) 1.17
Astrocytes produce the antiinflammatory and neuroprotective agent hydrogen sulfide. Neurobiol Aging (2009) 1.14
Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol (2007) 1.11
Expression of BRI, the normal precursor of the amyloid protein of familial British dementia, in human brain. Acta Neuropathol (2003) 1.10
Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J Neuropathol Exp Neurol (2006) 1.09
Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging (2002) 1.06
Pharmacologic approaches to the treatment of amyotrophic lateral sclerosis. BioDrugs (2005) 1.05
Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol Aging (2008) 1.03
Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim Biophys Acta (2009) 1.01
Non-steroidal anti-inflammatory drugs (NSAIDs) and other anti-inflammatory agents in the treatment of neurodegenerative disease. Curr Alzheimer Res (2005) 1.01
Proteolysis of non-phosphorylated and phosphorylated tau by thrombin. J Biol Chem (2004) 1.00
Hydrogen sulfide-releasing NSAIDs attenuate neuroinflammation induced by microglial and astrocytic activation. Glia (2010) 0.99
Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. Nat Med (2004) 0.98
Mechanisms of GABA release from human astrocytes. Glia (2011) 0.96
Expression of complement messenger RNAs and proteins by human oligodendroglial cells. Glia (2003) 0.96
Interferon-gamma-dependent cytotoxic activation of human astrocytes and astrocytoma cells. Neurobiol Aging (2008) 0.93
Enduring involvement of tau, beta-amyloid, alpha-synuclein, ubiquitin and TDP-43 pathology in the amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam (ALS/PDC). Acta Neuropathol (2008) 0.91
Anti-inflammatory effects of antidepressants: possibilities for preventives against Alzheimer's disease. Cent Nerv Syst Agents Med Chem (2009) 0.88
TDP-43 pathology in familial British dementia. Acta Neuropathol (2009) 0.88
Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. Neurobiol Aging (2012) 0.88
The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs (2007) 0.87
Block of purinergic P2X7R inhibits tumor growth in a C6 glioma brain tumor animal model. J Neuropathol Exp Neurol (2011) 0.86
Interleukin 1alpha and interleukin 6 protect human neuronal SH-SY5Y cells from oxidative damage. Neurosci Lett (2004) 0.86
Aurin tricarboxylic acid self-protects by inhibiting aberrant complement activation at the C3 convertase and C9 binding stages. Neurobiol Aging (2012) 0.86
Complement activated C4d immunoreactive oligodendrocytes delineate small cortical plaques in multiple sclerosis. Exp Neurol (2002) 0.85
Toxicity of human monocytic THP-1 cells and microglia toward SH-SY5Y neuroblastoma cells is reduced by inhibitors of 5-lipoxygenase and its activating protein FLAP. J Leukoc Biol (2003) 0.85
Comparison of Vascular Perturbations in an Aβ-Injected Animal Model and in AD Brain. Int J Alzheimers Dis (2011) 0.85
Optineurin in Huntington's disease intranuclear inclusions. Neurosci Lett (2011) 0.84
Differential expression of interferon-gamma receptor on human glial cells in vivo and in vitro. J Neuroimmunol (2010) 0.84
Proton pump inhibitors exert anti-inflammatory effects and decrease human microglial and monocytic THP-1 cell neurotoxicity. Exp Neurol (2009) 0.84
Differential pathways for interleukin-1β production activated by chromogranin A and amyloid β in microglia. Neurobiol Aging (2013) 0.83
Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease. Acta Neuropathol (2010) 0.83
Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein. J Biol Chem (2011) 0.83
Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. Biochem Biophys Res Commun (2007) 0.83
STAT3 inhibitors attenuate interferon-γ-induced neurotoxicity and inflammatory molecule production by human astrocytes. Neurobiol Dis (2010) 0.83
Prolyl endopeptidase is revealed following SILAC analysis to be a novel mediator of human microglial and THP-1 cell neurotoxicity. Glia (2008) 0.82
Mg2+ ions reduce microglial and THP-1 cell neurotoxicity by inhibiting Ca2+ entry through purinergic channels. Brain Res (2010) 0.82
Functional ryanodine receptors are expressed by human microglia and THP-1 cells: Their possible involvement in modulation of neurotoxicity. J Neurosci Res (2007) 0.82
Increase in core body temperature of Alzheimer's disease patients as a possible indicator of chronic neuroinflammation: a meta-analysis. Gerontology (2006) 0.82
Inhibition of human astrocyte and microglia neurotoxicity by calcium channel blockers. Neuropharmacology (2012) 0.82
Upregulation and expression patterns of the angiogenic transcription factor ets-1 in Alzheimer's disease brain. J Alzheimers Dis (2013) 0.81
GAD65, GAD67, and GABAT immunostaining in human brain and apparent GAD65 loss in Alzheimer's disease. J Alzheimers Dis (2013) 0.81
Modulation of human microglia and THP-1 cell toxicity by cytokines endogenous to the nervous system. Neurobiol Aging (2005) 0.81
Simple in vitro assays to identify amyloid-beta aggregation blockers for Alzheimer's disease therapy. J Alzheimers Dis (2010) 0.81
Proton pump inhibitors reduce interferon-γ-induced neurotoxicity and STAT3 phosphorylation of human astrocytes. Glia (2011) 0.81
Clinically tested drugs for Alzheimer's disease. Expert Opin Investig Drugs (2003) 0.80
Neurotoxic factors released by stimulated human monocytes and THP-1 cells. Brain Res (2011) 0.80
Purinergic responses of calcium-dependent signaling pathways in cultured adult human astrocytes. BMC Neurosci (2014) 0.79
Association of alleles carried at TNFA -850 and BAT1 -22 with Alzheimer's disease. J Neuroinflammation (2008) 0.79
Effects of obovatol on GSH depleted glia-mediated neurotoxicity and oxidative damage. J Neuroimmune Pharmacol (2011) 0.79
The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ. J Neuroinflammation (2012) 0.79
Chymotrypsin-like proteases contribute to human monocytic THP-1 cell as well as human microglial neurotoxicity. Glia (2005) 0.78
S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity. J Neuroimmunol (2004) 0.78
Amyloid-beta vaccination for Alzheimer's dementia. Lancet (2008) 0.78
Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathol (2007) 0.78
Effects of C-reactive protein and pentosan polysulphate on human complement activation. Immunology (2002) 0.78
Anti-inflammatory effects of cerebrocrast in a model of rat paw edema and on mononuclear THP-1 cells. Eur J Pharmacol (2002) 0.77
Optineurin is colocalized with ubiquitin in Marinesco bodies. Acta Neuropathol (2011) 0.77
Mechanisms of Mg2+ inhibition of BzATP-dependent Ca2+ responses in THP-1 monocytes. Brain Res (2012) 0.77
Weak BMAA toxicity compares with that of the dietary supplement β-alanine. Neurobiol Aging (2011) 0.76
Protein labeling and biotinylation of peptides during spot synthesis using biotin p-nitrophenyl ester (biotin-ONp). Proteomics (2008) 0.76
Adhesion of exogenous human microglia and THP-1 cells to amyloid plaques of postmortem Alzheimer's disease brain. J Alzheimers Dis (2008) 0.76
Abeta immunotherapy and other means to remove amyloid. Curr Drug Targets CNS Neurol Disord (2005) 0.76
Human oligodendroglial cells express low levels of C1 inhibitor and membrane cofactor protein mRNAs. J Neuroinflammation (2004) 0.76
Familial British dementia: colocalization of furin and ABri amyloid. Acta Neuropathol (2003) 0.76
Hot spots: can positron emission tomography offer insights into the pathogenesis of PD? Ann Neurol (2005) 0.75
The ALS/PDC syndrome of Guam and the cycad hypothesis. Neurology (2009) 0.75
A computer support system for neurological anatomical diagnosis. Clin Neurol Neurosurg (2008) 0.75
A Method for Diagnosing Alzheimer's Disease Based on Salivary Amyloid-β Protein 42 Levels. J Alzheimers Dis (2016) 0.75